Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants-Reference-Cited by-同舟云学术

Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants

Published:2022-08-22 Issue:9 Volume:31 Page:957-964
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Li Zonglin¹,Lin Chu¹^ORCID,Zhou Jinyu¹,Cai Xiaoling¹,Zhu Xingyun¹,Hu Suiyuan¹,Lv Fang¹,Yang Wenjia¹,Ji Linong¹^ORCID

Affiliation:

1. Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, China

Funder

National Natural Science Foundation of China

Beijing Natural Science Foundation

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2113056

Reference47 articles.

1. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

2. DPP4 inhibitors for diabetes—What next?

3. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)

4. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

5. DPP4 Inhibitors: a new approach in diabetes treatment

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition);AGING MEDICINE;2024-02

2. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study;BMJ Open Diabetes Research & Care;2023-11